DCTN2 and hepatocellular carcinoma: Moreover, rescue experiments using SC79, an AKT agonist,38 partially restored the proliferative and migratory abilities of HCC cells by silencing DCTN2, further supporting the involvement of the AKT pathway in DCTN2‐mediated tumour suppression.